With the demand for cell and gene therapies mounting, CDMO Cognate BioServices is looking to swiftly expand its U.S. headquarters with two new facilities—and it's not stopping there. Its dedicated ...

Cognate BioServices has acquired UK and Sweden-based Cobra Biologics, an advanced therapy CDMO that specializes in providing manufacturing services for the plasmid DNA and viral vector. No financial ...

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, began a multi-phase augmentation of its plasmid DNA services as a continuation of its gene therapy services’ expansion ...

EW Healthcare Partners has invested in Cognate BioServices. Financial terms weren’t announced. Cognate BioServices is a contract development and manufacturing organization. BALTIMORE and MEMPHIS, Tenn ...

(RTTNews) - Charles River Laboratories International, Inc. (CRL) reported fourth-quarter earnings per share on a non-GAAP basis of $2.39, an increase of 18.9% from last year. On average, 16 analysts ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc.

Cognate’s revenue for 2021 is projected at $140 million with the potential to grow 25% annually over the next five years. Memphis firm’s Cobra division helping develop COVID-19 vaccines Memphis ...

Charles River Laboratories plans to acquire the cell and gene therapy contract development and manufacturing organization (CDMO) Cognate BioServices for approximately $875 million cash, in a deal that ...

A Memphis-Shelby County economic development agency approved a $52 million tax break for a local biotechnology company, an incentive intended to persuade the firm to stay in Memphis to complete a $212 ...